The efficacy and safety of the Gefapixant in patients with interstitial lung disease
Not Applicable
Recruiting
- Conditions
- interstitial lung disease
- Registration Number
- JPRN-jRCT1031220275
- Lead Sponsor
- Abe Mitsuhiro
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Patients diagnosed with interstitial lung disease
Patients who have been fully informed of the study and given the consent
More than 18 years old patients
Exclusion Criteria
Patients unable to give the consent
Patients allergic to sulfonamide group
Other patients deemed unsuitable for the study by the principal investigator or the sub-investigator
Patients already taking gefapixant
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method